Mind Medicine (MindMed) Inc
NASDAQ:MNMD

Watchlist Manager
Mind Medicine (MindMed) Inc Logo
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Watchlist
Price: 7.32 USD 3.39% Market Closed
Market Cap: 536.8m USD
Have any thoughts about
Mind Medicine (MindMed) Inc?
Write Note

Mind Medicine (MindMed) Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mind Medicine (MindMed) Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Research & Development
-$53.7m
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
-120%
Canopy Growth Corp
TSX:WEED
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Research & Development
-CA$324k
CAGR 3-Years
13%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Research & Development
-$4.7m
CAGR 3-Years
42%
CAGR 5-Years
10%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Research & Development
-CA$20.2m
CAGR 3-Years
-16%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mind Medicine (MindMed) Inc
Glance View

Market Cap
536.8m USD
Industry
Pharmaceuticals

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.

MNMD Intrinsic Value
2.22 USD
Overvaluation 70%
Intrinsic Value
Price

See Also

What is Mind Medicine (MindMed) Inc's Research & Development?
Research & Development
-53.7m USD

Based on the financial report for Sep 30, 2024, Mind Medicine (MindMed) Inc's Research & Development amounts to -53.7m USD.

What is Mind Medicine (MindMed) Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-120%

Over the last year, the Research & Development growth was -30%. The average annual Research & Development growth rates for Mind Medicine (MindMed) Inc have been -20% over the past three years , and -120% over the past ten years .

Back to Top